Sygnature Discovery, a preclinical services provider, has purchased Peak Proteins. This transaction represents the first acquisition since Five Arrows Principal Investments made a significant equity investment in the company in 2021. Five Arrows Principal Investments is part of Rothschild & Co’s merchant banking business which manages over €18 billion.

Sygnature Discovery is an integrated drug discovery and non-clinical services company. The company operates fully enabled research facilities in the UK, housing more than 400 research scientists. Peak Proteins is a research organization that provides protein reagents, protein structure information, and protein mass spectrometry services. The acquisition is part of Sygnature’s strategic plan to invest in the expansion of its drug discovery capabilities.

“We are delighted to welcome Peak Proteins and its talented scientists to the Sygnature family,“ said Sygnature Discovery’s CEO Simon Hirst. “Accessing high quality proteins efficiently is often a major stumbling for projects and protein structural information is still the gold standard when it comes to drug design. The closer integration of Peak Proteins into our projects will be extremely powerful in driving programmes forward.”